Predictive Oncology (POAI) Corporate Media Kit

Through its subsidiaries and valuable portfolio, Predictive Oncology is targeting several underserved and multibillion treatment markets through multiple collaborations and partnerships across: Cancer Diagnostics, Personaliz edMedicine and Treatments: Helomics is engaged with the following: D Ovarian Cancer: Collaborating with the University of Pittsburgh Medical Center (UPMC), Magee Women's Hospital and the University of Pittsburgh in a study of the use of artificial intelligence to improve clinical decision making for ovarian cancer patients as well as use these AI-driven predictive models for the development of new therapies for ovarian cancer with Pharma and biotech partners. D Thyroid Cancer: Strategic agreement with Interpace Diagnostics Group Inc. (IDXG) to develop AI-driven models to diagnoseand assess the risk for thyroid cancer, as well as provide appropriate predictions of prognosis.